Health
The U.S. Food and Drug Administration (FDA) said Monday that makers of GLP-1 drugs must add information about a potential increased risk of a rare eye condition that can cause permanent vision loss to the warnings and precautions section of their labels.
FDA Orders Vision Loss Warning on 12 GLP-1 Drugs